Clinical Features and Treatment Results of Metastatic Breast Cancer Patients: A Single Center Experience

Yıl 2020, , 75 - 80, 13.06.2020

Mahmut Büyükşimşek , Semra Paydaş , Servet Başdoğan Mustafa Toğun Abdullah Evren Yetişir Cem Mirili , Ali Oğul , Mert Tohumcuoğlu

https://doi.org/10.21673/anadoluklin.641856

Öz

Aim: Breast
cancer is the most common cancer that causes death in women. We wanted to investigate
the clinical features and treatment results of patients with metastatic breast
cancer.

Materials and Methods:
Sixty-five patients with metastatic breast cancer followed in the Oncology
Department of Cukurova University between 2011 and 2017 were included in the
study. The clinical features and treatments of the patients were investigated
retrospectively.

Results: The
majority of patients had only bone metastases. Re-biopsy was performed in 66,6%
of 45 patients who subsequently underwent metastatic stage; and tumor biology
had changed in 20% of these patients. The progression-free
survival in the metastatic stage was 10 months and the overall survival was 34
months.

Discussion and Conclusion:
Survival
of patients with metastatic breast cancer is consistent with the literature.
When new agents and new therapies are also taken into consideration, re-biopsy
at relapses is critical in considering the possibility of changes in disease
biology.

Anahtar Kelimeler

metastatic breast cancer, survival results, chemotherapy, targeted treatments

Metastatik Meme Kanserli Hastaların Klinik Özellikleri ve Tedavi Sonuçları: Tek Merkez Deneyimi

Öz

Amaç:
Meme kanseri
kadınlarda en sık görülen ve en sık ölüme neden olan kanserdir. Biz
de merkezimizde takip ettiğimiz metastatik meme kanseri (MMK) olan hastaların klinik
özelliklerini ve tedavi sonuçlarını araştırmak istedik.

Gereç
ve Yöntemler: Çukurova
Üniversitesi Onkoloji bilim dalında 2011-2017 yılları arasında takip edilen 65 MMK
olan hasta çalışmaya dahil edildi. Hastaların klinik özellikleri ve aldıkları
tedaviler retrospektif olarak araştırıldı.

Bulgular:
Hastaların büyük
çoğunluğunda sadece kemik metastazı vardı. Sonradan metastatik evreye geçen 45
hastanın %66,6’ sına yeniden biyopsi yapıldı; bu hastaların %20’ sinde tümör
biyolojisi değişmişti. Metastatik evrede progresyonsuz sağkalım 10 ay, ortalama
sağkalım 34 ay olarak hesaplandı.

Tartışma ve Sonuç: MMK
olan hastalarda literatürle uyumlu sağkalımlar elde edilmiştir. Yeni kullanıma
giren ajanlar ve hedefleyici tedavilerdeki gelişmeler de göz önüne alındığında
hastalık biyolojisindeki değişme ihtimali göz önünde bulundurularak relapslarda
yeniden biyopsi yapılması kritik önemdedir.

Anahtar Kelimeler

metastatik meme kanseri, sağkalım sonuçları, kemoterapi, hedefleyici tedaviler

Kaynakça

• Referans1 Winters S, Martin C, Murphy D, Shokar NK. Breast Cancer Epidemiology, Prevention, and Screening. Prog Mol Biol Transl Sci. 2017;151:1-32. doi: 10.1016/bs.pmbts.2017.07.002.
• Referans2 Güth U, Elfgen C, Montagna G, Schmid SM. Long-Term Survival and Cure in Distant Metastatic Breast Cancer. Oncology. 2019;97(2):82-93. doi: 10.1159/000500298. Epub 2019 May 3.
• Referans3 Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, ve ark. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010 Jul;134(7):e48-72. Referans4 Bansal C, Singh US, Misra S, Sharma KL, Tiwari V, Srivastava AN. Comparative evaluation of the modified Scarff-Bloom-Richardson grading system on breast carcinoma aspirates and histopathology. Cytojournal. 2012;9:4.
• Referans5 Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011 Aug;22(8):1736-47.
• Referans6 Ogiya R, Sagara Y, Niikura N, Freedman RA. Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer. Clin Breast Cancer. 2019 Jun;19(3):200-207.e1. doi: 10.1016/j.clbc.2019.01.005.
• Referans7 Leone BA, Vallejo CT, Romero AO, Machiavelli MR, Pérez JE, Leone J, ve ark. Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis. Breast Cancer Res Treat. 2017 Feb;161(3):537-548. doi: 10.1007/s10549-016-4066-7.
• Referans8 Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, ve ark. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004 Aug 15;22(16):3302-8.
• Referans9 Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol. 2010 Nov;21(11):2169-74. doi: 10.1093/annonc/mdq220.
• Referans10 Pal SK, Dehaven M, Nelson RA, Onami S, Hsu J, Waliany S, ve ark. Impact of modern chemotherapy on the survival women presenting with de no metastatic breast cancer. BMC Cancer. 2012 Sep 28;12:435. doi: 10.1186/1471-2407-12-435. Referans11 Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, ve ark. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancerreceive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol. 2016 Feb;27(2):256-62. doi: 10.1093/annonc/mdv544. Referans12 Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, ve ark. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev. 2012 Oct;38(6):708-14. doi: 10.1016/j.ctrv.2011.11.006.
• Referans13 de Dueñas EM, Hernández AL, Zotano AG, Carrión RM, López-Muñiz JI, Novoa SA, ve ark. Prospective evaluation of the conversion rate in the receptor status between primary breastcancer and metastasis: results from the GEICAM 2009-03 ConvertHER study. Breast Cancer Res Treat. 2014 Feb;143(3):507-15. doi: 10.1007/s10549-013-2825-2.